

## Classical hodgkin lymphoma

### ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) ± RT

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Doxorubicin	25 mg/m <sup>2</sup>	1, 15	Q4W	1~3
Bleomycin	10 units/m <sup>2</sup>	1, 15		
Vinblastine	6 mg/m <sup>2</sup>	1, 15		
Dacarbazine	375 mg/m <sup>2</sup>	1, 15		

### Stanford V (doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone)\*

Doxorubicin	25 mg/m <sup>2</sup>	1, 15	Q4W	4~6
Vinblastine	6 mg/m <sup>2</sup>	1, 15		
Mechlorethamine (※)	6 mg/m <sup>2</sup>	1		
Etoposide	60 mg/m <sup>2</sup>	15, 16		
Vincristine	1.4 mg/m <sup>2</sup>	8, 22		
Bleomycin	5 units/m <sup>2</sup>	8, 22		
Prednisone	40 mg/m <sup>2</sup>		QOD	

\*cyclophosphamide may be used as an alternate to nitrogen mustard

## 參考文獻

1. Eich HT, Diehl V, Gorgens H, et al. Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial. *J Clin Oncol* 2010; 28: 4199-4206.
2. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's Lymphoma. *N Engl J Med* 2012; 366:399-408
3. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-Term Results. *J Clin Oncol* 2004; 22(14):2835-2841.
4. Gordon LI, Hong F, Fisher RI et al. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation in locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Oncol 2013; 31:684-691.
5. Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. *Ann Oncol* 2013; 24:1044-1048.
6. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. *Ann Oncol* 2010; 21:574-581.

## Nodular Lymphocyte-Predominant Hodgkin Lymphoma<sup>1</sup>

### ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Doxorubicin	25 mg/m <sup>2</sup>	1, 15	Q4W	1~2
Bleomycin	10 units/m <sup>2</sup>	1, 15		
Vinblastine	6 mg/m <sup>2</sup>	1, 15		
Dacarbazine	375 mg/m <sup>2</sup>	1, 15		
± Rituximab	375 mg/m <sup>2</sup>	1		

### CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q3W	3
Doxorubicin	50 mg/m <sup>2</sup>	1		
Vincristine	1.4 mg/m <sup>2</sup>	1		
Prednisone	40 mg/m <sup>2</sup> /day	1~5		
± Rituximab	375 mg/m <sup>2</sup>	1		

### CVP (cyclophosphamide, vincristine, prednisone) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q3W	
Vincristine	1.4 mg/m <sup>2</sup>	1		
Prednisone	40 mg/m <sup>2</sup> /day	1~5		
± Rituximab	375 mg/m <sup>2</sup>	1		

**Rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	QW	4

**參考文獻**

- 1 Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. *Blood* 2011;118:4585-4590.
- 2 Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's Lymphoma? *J Clin Oncol* 2010;28:e8.
- 3 Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. *ASH Annual Meeting Abstracts* 2010;116:2812.
- 4 Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. *Blood* 2011;118:4363-4365.

## Systemic therapy for relapsed or refractory disease

### Second-Line Chemotherapy:

#### DHAP (dexamethasone, cisplatin, high-dose cytarabine) <sup>19,20</sup>

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Dexamethasone	40 mg	1~4	Q3W~Q4W	1.2
Cisplatin	100 mg/m <sup>2</sup>	1		1.2
Cytarabine	2000 mg/m <sup>2</sup>	2		1.2

#### ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) <sup>21,22</sup>

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Etoposide	40 mg/m <sup>2</sup>	1~4	Q3W~Q4W	3.4
Methylprednisolone	500 mg	1~4		3.4
Cisplatin	25 mg/m <sup>2</sup>	1~4		3.4
Cytarabine	2000 mg/m <sup>2</sup>	5		3.4

#### GCD (gemcitabine, carboplatin, dexamethasone)± rituximab <sup>23</sup>

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1000 mg/m <sup>2</sup>	1,8	Q3W	5
Carboplatin	AUC =5	1		5
Dexamethasone	40 mg/day	1~4		5
Rituximab	375 mg/m <sup>2</sup>	8		5

**GVD (gemcitabine, vinorelbine, liposomal doxorubicin) <sup>24</sup>**
**(1) For transplant-naïve patients**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1000 mg/m <sup>2</sup>	1,8	Q3W	6
Vinorelbine	20 mg/m <sup>2</sup>	1,8		6
Liposomal doxorubicin	15 mg/m <sup>2</sup>	1,8		6

**(2) For post-transplant patients**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	800 mg/m <sup>2</sup>	1,8	Q3W	6
Vinorelbine	15 mg/m <sup>2</sup>	1,8		6
Liposomal doxorubicin	10 mg/m <sup>2</sup>	1,8		6

**ICE (ifosfamide, carboplatin, etoposide) <sup>25,26</sup>**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Etoposide	100 mg/m <sup>2</sup>	1~3	Q3W	7.8
Carboplatin	AUC =5	2		7.8
Ifosfamide	5000 mg/m <sup>2</sup>	2		7.8

**R-ICE (ifosfamide, carboplatin, etoposide) <sup>25,26</sup>**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	7.8
Etoposide	100 mg/m <sup>2</sup>	1~3		7.8
Carboplatin	AUC =5	2		7.8
Ifosfamide	5000 mg/m <sup>2</sup>	2		7.8

**IGEV (ifosfamide, gemcitabine, vinorelbine)<sup>27</sup>**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Ifosfamide	2000 mg/m <sup>2</sup>	1~4	Q3W	9
Gemcitabine	800 mg/m <sup>2</sup>	1,4		9
Vinorelbine	20 mg/m <sup>2</sup>	1		9
Prednisolone	100 mg	1~4		9

**Mini-BEAM (carmustine, cytarabine, etoposide, melphalan)<sup>28,29</sup>**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Carmustine(BCNU)	60 mg/m <sup>2</sup>	1	Q4W~Q6W	10.11
Cytarabine	100 mg/m <sup>2</sup>	2~5		10.11
Etoposide	75 mg/m <sup>2</sup>	2~5		10.11
Melphalan	30 mg/m <sup>2</sup>	6		10.11

**MINE (mesna, ifosfamide, mitoxantrone, etoposide)<sup>30</sup>**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Mesna	1300 mg/m <sup>2</sup>	1~3	Q3W~Q4W	12
Ifosfamide	1300 mg/m <sup>2</sup>	1~3		12
Mitoxantrone	8 mg/m <sup>2</sup>	1		12
Etoposide	65 mg/m <sup>2</sup>	1~3		12

## 參考文獻

1. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol* 2002;13(10):1628-1635.
2. Abali H, Urün Y, Oksüzö lu B, Budako lu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. *Cancer Invest* 2008;26(4):401-406.
3. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. *Ann Oncol* 1999;10(5):593-595.
4. Fernández de Larrea C, Martínez C, et al. Salvage chemotherapy with alternating MINEESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem cell transplantation. *Ann Oncol* 2010;21(6):1211-1216.
5. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by Puget Sound Oncology Consortium. *Leuk Lymphoma* 2010;51:1523-1529.
6. Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. *Ann Oncol* 2007;18(6):1071-1079.
7. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood* 2001;97(3):616-623.
8. Abali H, Urün Y, Oksüzö lu B, Budako lu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. *Cancer Invest* 2008;26(4):401-406.
9. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. *Haematologica* 2007;92(1):35-41.
10. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. *J Clin Oncol* 1995;13:396-402.



11. Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. *Br J Haematol* 2001;113(1):161-171.
12. odriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ ifosfamide, mitoxantrone and etoposide for refractory lymphoms. *Ann Oncol* 1995;6(6):609-611.

## Additional therapy options: (only for CHL)

### Bendamustine <sup>31</sup>

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Bendamustine	120 mg/m <sup>2</sup>	1,2	Q4W	1

### Everolimus <sup>32</sup>

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Everolimus	10 mg		QD	2

## 參考文獻

1. Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. *J Clin Oncol* 2013;31:456-460.
2. Johnston PB, Inwards DJ, Colgan JP, et al; A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. *Am J Hematol*. 2010;85(5):320-4.

## Diffuse Large B-Cell Lymphoma

### First-line Therapy

#### RCHOP

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	1
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q3W	
Doxorubicin	50 mg/m <sup>2</sup>	1	Q3W	
Vincristine	1.4 mg/m <sup>2</sup>	1	Q3W	
Prednisone	100 mg/day	1~5	Q3W	

#### Dose-dense RCHOP<sup>14</sup>

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q2W	2
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q2W	
Doxorubicin	50 mg/m <sup>2</sup>	1	Q2W	
Vincristine	1.4 mg/m <sup>2</sup>	1	Q2W	
Prednisone	100 mg/day	1~5	Q2W	

### Dose-adjusted EPOCH+rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	3
Etoposide	50 mg/m <sup>2</sup> /day	1~4	Q3W	
Doxorubicin	10mg/m <sup>2</sup> /day	1~4	Q3W	
Vincristine	0.4 mg/m <sup>2</sup> /day	1~4	Q3W	
Cyclophosphamide	750 mg/m <sup>2</sup> /day	5	Q3W	
Prednisone	60 mg/m <sup>2</sup>	1~5	Q3W	

### First-line Therapy for patients with Poor Left Ventricular Function

#### RCDOP+rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	4
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q3W	
Liposomal doxorubicin	30 mg/m <sup>2</sup>	1	Q3W	
Vincristine	1.4 mg/m <sup>2</sup>	1	Q3W	
Prednisone	60 mg/m <sup>2</sup> /day	1~5	Q3W	

#### RCNOP+rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	5
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q3W	
Mitoxantrone	10 mg/m <sup>2</sup>	1	Q3W	
Vincristine	1.4 mg/m <sup>2</sup>	1	Q3W	
Prednisone	50 mg/m <sup>2</sup>	1~5	Q3W	

**DA-EPOCH+ rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	3
Etoposide	50mg/m <sup>2</sup> /day	1~4	Q3W	
Doxorubicin	10mg/m <sup>2</sup> /day	1~4	Q3W	
Vincristine	0.4mg/m <sup>2</sup> /day	1~4	Q3W	
Cyclophosphamide	750mg/m <sup>2</sup> /day	5	Q3W	
Prednisone	60mg/m <sup>2</sup>	1~5	Q3W	

**RCEOP**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	6
Cyclophosphamide	750 mg/m <sup>2</sup>	1		
Etoposide	50 mg/m <sup>2</sup>	1		
	100 mg/m <sup>2</sup>	2, 3		
Vincristine	1.4 mg/m <sup>2</sup>	1		
Prednisone	100 mg/m <sup>2</sup> /day	1~5		

**TREC (rituximab , Bendamustine, etoposide, carboplatin)**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	19
Bendamustine	90-120 mg/m <sup>2</sup>	1~2	Q3W	
Etoposide	100 mg/m <sup>2</sup>	1~3	Q3W	
Carboplatin	AUC 5	1	Q3W	

## Patients >80years of age with comorbidities

### R-mini-CHOP

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	7
Cyclophosphamide	400 mg/m <sup>2</sup>	1	Q3W	
Doxorubicin	25 mg/m <sup>2</sup>	1	Q3W	
Vincristine	1 mg	1	Q3W	
Prednisone	40 mg/m <sup>2</sup>	1~5	Q3W	

## Concurrent presentation with CNS disease

### Parenchymal

3g/m<sup>2</sup> or more of systemic methotrexate given on Day 15 of a 21-day RCHOP cycle that has been supported by growth factors.

### Leptomeningeal

IT methotrexate/cytarabine, consider Ommaya reservoir placement and/or systemic methotrexate (3-3.5 g/m<sup>2</sup>)

## Second-line Therapy (intention to proceed to high-dose therapy)

### DHAP (dexamethasone, cisplatin, cytarabine) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Cisplatin	100 mg/m <sup>2</sup>	1	Q3-4W	8
Cytarabine	2000 mg/m <sup>2</sup>	2	Q3-4W	
Dexamethasone	40 mg	1~4	Q3-4W	

**ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) ± rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Etoposide	40 mg/m <sup>2</sup>	1~4	Q3-4W	9
Methylprednisolone	500 mg	1~4	Q3-4W	
Cytarabine	2,000 mg/m <sup>2</sup>	5	Q3-4W	
Cisplatin	25 mg/m <sup>2</sup>	1~4	Q3-4W	
Rituximab	375 mg/m <sup>2</sup>	1	Q3-4W	

**GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab or (gemcitabine, dexamethasone, carboplatin) ± rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1,000 mg/m <sup>2</sup>	1, 8	Q3W	10
Dexamethasone	40 mg	1~4	Q3W	
Cisplatin	25 mg/m <sup>2</sup>	1~3	Q3W	
Rituximab	375 mg/m <sup>2</sup>	8	Q3W	

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1,000 mg/m <sup>2</sup>	1, 8	Q3W	10
Dexamethasone	40 mg	1~4	Q3W	
Carboplatin	AUC=5	1	Q3W	
Rituximab	375 mg/m <sup>2</sup>	8	Q3W	

### GemOx (gemcitabine , oxaliplatin ) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1,000 mg/m <sup>2</sup>	2		11
Oxaliplatin	100 mg/m <sup>2</sup>	2		
Rituximab	375 mg/m <sup>2</sup>	1		

### ICE (ifosfamide, carboplatin , etoposide) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Etoposide	100 mg/m <sup>2</sup>	1~3	Q2W	12
Carboplatin	AUC=5	2	Q2W	
Ifosfamide	5,000 mg/m <sup>2</sup>	2	Q2W	
Rituximab	375 mg/m <sup>2</sup>	1	Q2W	

### MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Mesna	1,330 mg/m <sup>2</sup>	1~3		13
Ifosfamide	1,330 mg/m <sup>2</sup>	1~3		
Mitoxantrone	8 mg/m <sup>2</sup>	1		
Etoposide	65 mg/m <sup>2</sup>	1~3		
Rituximab	375 mg/m <sup>2</sup>	1		

## Second-line Therapy (non-candidates for high-dose therapy)

### Bendamustine ± rituximab

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Bendamustin	120 mg/m <sup>2</sup>	1~2	Q3W	14
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	



**CEOP (cyclophosphamide, etoposide, vincristine, prednisone) ± rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Cyclophosphamide	750 mg/m <sup>2</sup>	1	Q3W	6
Etoposide	50 mg/m <sup>2</sup>	1	Q3W	
Etoposide	100 mg/m <sup>2</sup>	2~3	Q3W	
Vincristine	1.4 mg/m <sup>2</sup>	1	Q3W	
Prednisone	100 mg	1~5	Q3W	
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	

**DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) ± rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Etoposide	50 mg/m <sup>2</sup>	1~4	Q3W	15
Doxorubicin	10 mg/m <sup>2</sup>	1~4	Q3W	
Vincristine	0.4 mg/m <sup>2</sup>	1~4	Q3W	
Cyclophosphamide	750 mg/m <sup>2</sup>	5	Q3W	
Prednisone	60 mg/m <sup>2</sup>	1~5	Q3W	
Rituximab	375 mg/m <sup>2</sup>	1	Q3W	

**GDP ± rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1,000 mg/m <sup>2</sup>	1, 8	Q3W	16
Dexamethasone	40 mg	1~4	Q3W	
Cisplatin	75 mg/m <sup>2</sup>	1	Q3W	

**GemOx ± rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1,200 mg/m <sup>2</sup>	1, 8	Q3W	17
Oxaliplatin	120 mg/m <sup>2</sup>	2	Q3W	

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Gemcitabine	1,000-1,200 mg/m <sup>2</sup>	1, 8	Q2W	17
Oxaliplatin	100-120 mg/m <sup>2</sup>	2	Q2W	
Rituximab	375 mg/m <sup>2</sup>	1	Q2W	

**Rituximab**

藥品名	劑量/m <sup>2</sup>	給藥日	頻率	參考文獻
Rituximab	375 mg/m <sup>2</sup>	1	QW	18

**參考文獻**

- 1 Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood* 2010;116:2040-2045.
- 2 Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet* 2013;381:1817-1826.
- 3 Purroy N, Lopez A, Vallespi T, Gironella M, Bergua J, Sancho JM. Dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor risk large B-cell lymphoma. A phase 2 study conducted by the Spanish PETHEMA Group [Abstract]. *Blood* 2009;114:Abstract 2701.

- 4 Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study. *Haematologica* 2002;87:822-827.
- 5 Bessell EM, Burton A, Haynes AP, et al. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. *Ann Oncol* 2003;14:258-267.
- 6 Moccia A, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): Excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines [abstract]. *Blood* 2009;114:Abstract 408.
- 7 Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2011;12:460-468.
- 8 Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010;28:4184-4190.
- 9 Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. *Haematologica* 2008;93:1829-1836.
- 10 Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by the Puget Sound Oncology Consortium. *Leuk Lymphoma* 2010;51:1523-1529.
- 11 Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. *Eur J Haematol* 2008;80:127-132.
- 12 Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010;28:4184-4190.
- 13 Rodriguez MA, Cabanillas FC, Hagemester FB, et al. A phase II trial of mesna/ ifosfamide, mitoxantrone and etoposide for refractory lymphomas. *Ann Oncol* 1995;6(6):609-611.
- 14 Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. *Ann Hematol* 2014;93:403-409.

- 15 Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DAEPOCH- rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. *Haematologica* 2012;97:758-765.
- 16 Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). *Cancer* 2004;101:1835-1842.
- 17 Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. *Cancer Chemother Pharmacol* 2009;64:907-916.
- 18 Maloney DG, Grillo= Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin' s Lymphoma. *Blood* 1997;90(6):2188-2195.
- 19 Lihua Elizabeth Budde, MD, PhD, et al.ull Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma. Monday, December 10, 2012